Debiopharm hails strong results with HCV drug

27 April 2009

Swiss drugmaker Debiopharm has presented results from a Phase IIa study with Debio 025, a selective cyclophilin inhibitor with a potent  anti-hepatitis C effect at the annual meeting of the European  Association for the Study of the Liver, in Copenhagen, Denmark.

The Phase IIa study investigated the efficacy and safety of Debio 025 in  combination with Peg-interferon alpha 2a and ribavirin in previously  null-responder genotype 1 HCV patients. Results demonstrated that Debio  025 at doses of 400mg (with initial loading) and 800mg daily for 29 days  showed a statistically-significant reduction of HCV RNA of respectively  -1.96 log (-98.9%) and -2.38 log (-99.5%) when co-administered with  Peg-IFN alpha-2a and ribavirin in previous null responders.

"These results in patients who are highly unlikely to respond to  retreatment with an interferon-based regimen, are very important to us,  as they confirm that Debio 025 is a potent anti-HCV agent," said  Rolland-Yves Mauvernay, founder of Debiopharm.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight